Mechanism of action<unk>  is a fully human monoclonal antibody blocking the calcitonin gene-related peptide receptor (CGRPR). Pharmacokinetics After subcutaneous injection, the<unk>  has an estimated bioavailability of 82%. Highest blood plasma concentrations are reached after four to six days. Like other proteins, the substance is degraded by proteolysis to small peptides and amino acids. It has an elimination half-life of 28 days.
Erenumab
Anifrolumab
Alirocumab
Evolocumab
Emapalumab
Burosumab
Tralokinumab
Olaratumab